Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Trial Profile

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Apixaban (Primary) ; Aspirin
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ARCADIA
  • Most Recent Events

    • 17 Feb 2018 Planned primary completion date changed from 31 Oct 2021 to 18 Jan 2022.
    • 17 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 22 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top